Thu, January 16, 2025
Wed, January 15, 2025

AbbVie and Simcere Zaiming link to develop trispecific antibody

  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. aiming-link-to-develop-trispecific-antibody.html
  Print publication without navigation Published in Science and Technology on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.
AbbVie, a leading biopharmaceutical company, has entered into a collaboration with Simcere Zaiming, a Chinese biotech firm, to develop a trispecific antibody aimed at treating cancer. This partnership leverages Simcere Zaiming's expertise in trispecific T cell-engaging antibodies, which are designed to simultaneously target three different antigens, potentially enhancing the effectiveness of cancer immunotherapy. The agreement includes AbbVie making an upfront payment to Simcere Zaiming, with further milestone payments and royalties on future sales if the product successfully reaches the market. This collaboration not only signifies AbbVie's commitment to expanding its oncology portfolio but also highlights the growing trend of international partnerships in the biotech industry to accelerate drug development.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/abbvie-and-simcere-zaiming-link-to-develop-trispecific-antibody/ar-AA1xgBc4 ]